Exchange of beta-blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial).

@article{Lenarda2005ExchangeOB,
  title={Exchange of beta-blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial).},
  author={Andrea di Lenarda and Willem J. Remme and Andrew Charlesworth and John G. F. Cleland and Beatrix Lutiger and Marco Metra and Michel Komajda and Christian Torp-Pedersen and Armin Scherhag and Karl Swedberg and P Poole-wilson},
  journal={European journal of heart failure},
  year={2005},
  volume={7 4},
  pages={640-9}
}
BACKGROUND The Carvedilol or Metoprolol European Trial (COMET) reported a significant survival benefit for carvedilol, a beta1-, beta2- and alpha1-blocker, vs. metoprolol tartrate, a beta1-selective blocker, in patients with mild-to-severe chronic heart failure (CHF). Patients on treatment with metoprolol might benefit from switching to carvedilol. AIM To investigate the safety and tolerability of switching beta-blockers in CHF. METHODS At the end of COMET, the Steering Committee… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

Similar Papers

Loading similar papers…